| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J9271 |
Injection, pembrolizumab, 1 mg |
1,850 |
1,439 |
$24.52M |
| 0450 |
Emergency room services |
125,650 |
112,093 |
$11.28M |
| 0510 |
|
226,873 |
180,117 |
$8.06M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
5,499 |
5,443 |
$7.54M |
| J9035 |
Injection, bevacizumab, 10 mg |
3,421 |
1,702 |
$7.02M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
9,046 |
8,953 |
$6.93M |
| 77386 |
|
12,482 |
1,337 |
$6.20M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
21,794 |
21,223 |
$5.80M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,536 |
9,389 |
$5.50M |
| J9299 |
Injection, nivolumab, 1 mg |
798 |
433 |
$5.18M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
1,148 |
830 |
$4.98M |
| 80053 |
Comprehensive metabolic panel |
219,562 |
164,799 |
$4.51M |
| J2350 |
Injection, ocrelizumab, 1 mg |
158 |
144 |
$4.28M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
26,840 |
25,796 |
$4.10M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
867 |
564 |
$3.99M |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
49,751 |
44,307 |
$3.87M |
| J0897 |
Injection, denosumab, 1 mg |
1,966 |
1,866 |
$3.81M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
4,107 |
3,396 |
$3.77M |
| Q3014 |
Telehealth originating site facility fee |
174,959 |
141,554 |
$3.45M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,155 |
5,979 |
$3.13M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
1,170 |
795 |
$2.98M |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
1,258 |
962 |
$2.91M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
12,209 |
12,012 |
$2.77M |
| J2323 |
Injection, natalizumab, 1 mg |
379 |
350 |
$2.72M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
8,254 |
7,556 |
$2.68M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
67,625 |
56,033 |
$2.67M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
12,260 |
12,106 |
$2.58M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
114,658 |
87,268 |
$2.54M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
31,784 |
28,175 |
$2.40M |
| J0178 |
Injection, aflibercept, 1 mg |
2,470 |
2,319 |
$2.35M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
207,403 |
153,249 |
$2.35M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
20,505 |
16,133 |
$2.12M |
| 78816 |
|
1,191 |
1,179 |
$1.97M |
| 74183 |
|
5,316 |
5,251 |
$1.86M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
5,298 |
5,176 |
$1.82M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
33,200 |
25,344 |
$1.75M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
26,730 |
17,355 |
$1.73M |
| J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg |
958 |
296 |
$1.73M |
| 70450 |
Computed tomography, head or brain; without contrast material |
9,535 |
9,149 |
$1.72M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
51,868 |
47,024 |
$1.66M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
6,478 |
5,822 |
$1.54M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,657 |
2,102 |
$1.54M |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
5,186 |
5,127 |
$1.51M |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
2,971 |
2,923 |
$1.46M |
| 72197 |
|
3,769 |
3,645 |
$1.35M |
| 74174 |
|
2,060 |
2,033 |
$1.32M |
| 99070 |
|
162,369 |
56,759 |
$1.21M |
| 77300 |
|
2,747 |
2,432 |
$1.20M |
| 72156 |
|
1,211 |
1,203 |
$1.20M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
151 |
78 |
$1.19M |
| 77295 |
|
1,386 |
1,146 |
$1.18M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
16,047 |
14,956 |
$1.13M |
| 77301 |
|
924 |
869 |
$1.09M |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
2,987 |
2,970 |
$1.07M |
| 77373 |
|
710 |
254 |
$1.06M |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
365 |
120 |
$1.06M |
| 71250 |
|
6,142 |
6,077 |
$1.06M |
| 72157 |
|
1,198 |
1,188 |
$1.03M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
18,402 |
13,112 |
$997K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
3,503 |
3,414 |
$866K |
| 93975 |
|
3,654 |
3,587 |
$845K |
| 71046 |
Radiologic examination, chest; 2 views |
26,050 |
24,000 |
$829K |
| 72158 |
|
931 |
920 |
$823K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
9,002 |
6,583 |
$817K |
| 77334 |
|
3,594 |
2,349 |
$755K |
| 72141 |
|
1,697 |
1,687 |
$746K |
| 70543 |
|
1,687 |
1,675 |
$736K |
| 99201 |
|
1,539 |
1,258 |
$712K |
| 97139 |
|
33,873 |
10,758 |
$692K |
| 83735 |
|
43,619 |
26,834 |
$690K |
| 84443 |
Thyroid stimulating hormone (TSH) |
33,209 |
30,667 |
$686K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
2,670 |
1,889 |
$683K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
32,283 |
28,877 |
$681K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,845 |
1,733 |
$673K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
21,920 |
15,838 |
$649K |
| 87632 |
|
3,711 |
3,609 |
$633K |
| 0762 |
|
8,427 |
5,450 |
$617K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
2,028 |
2,026 |
$591K |
| 70498 |
|
1,579 |
1,557 |
$579K |
| J1453 |
Injection, fosaprepitant, 1 mg |
4,396 |
3,000 |
$577K |
| 84484 |
|
28,980 |
24,685 |
$565K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
283 |
106 |
$562K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
9,491 |
7,748 |
$554K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
38,669 |
36,939 |
$552K |
| 93970 |
|
3,280 |
3,218 |
$551K |
| J9312 |
Injection, rituximab, 10 mg |
129 |
53 |
$544K |
| 0370 |
|
3,133 |
2,965 |
$533K |
| 82803 |
|
14,258 |
13,153 |
$526K |
| 70496 |
|
1,608 |
1,588 |
$519K |
| J3490 |
Unclassified drugs |
52,858 |
20,196 |
$513K |
| 80197 |
|
27,871 |
14,346 |
$508K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
6,859 |
4,549 |
$506K |
| 96367 |
|
7,742 |
5,631 |
$500K |
| 0250 |
|
25,049 |
10,083 |
$491K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
7,202 |
6,407 |
$491K |
| 87507 |
|
1,103 |
1,085 |
$490K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
6,449 |
6,401 |
$485K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
9,489 |
9,231 |
$470K |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
11,514 |
11,187 |
$460K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
6,403 |
6,205 |
$436K |
| 96417 |
|
7,214 |
4,845 |
$430K |
| 77412 |
|
5,547 |
836 |
$429K |
| 87497 |
|
8,399 |
5,193 |
$422K |
| 96415 |
|
7,253 |
5,342 |
$419K |
| 0270 |
|
77,702 |
21,585 |
$411K |
| 93976 |
|
2,641 |
2,620 |
$408K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
14,625 |
14,303 |
$401K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
9,768 |
8,537 |
$401K |
| 93350 |
|
3,081 |
3,047 |
$396K |
| 70544 |
|
1,476 |
1,443 |
$394K |
| 86850 |
|
25,112 |
19,011 |
$388K |
| 70486 |
|
1,719 |
1,703 |
$375K |
| 92557 |
|
6,976 |
6,911 |
$365K |
| 86832 |
|
2,480 |
2,399 |
$365K |
| 86923 |
|
3,301 |
2,740 |
$360K |
| 93971 |
|
3,295 |
3,193 |
$359K |
| 81382 |
|
471 |
401 |
$358K |
| 81001 |
|
58,224 |
53,905 |
$356K |
| 88185 |
|
862 |
794 |
$351K |
| 77338 |
|
1,018 |
913 |
$351K |
| 72131 |
|
1,504 |
1,490 |
$348K |
| 74160 |
|
1,389 |
1,376 |
$347K |
| 93325 |
|
3,156 |
3,102 |
$344K |
| 93017 |
|
3,968 |
3,908 |
$341K |
| 71045 |
Radiologic examination, chest; single view |
18,022 |
17,014 |
$332K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,190 |
1,109 |
$332K |
| 97750 |
|
7,978 |
5,407 |
$323K |
| 77336 |
|
5,486 |
3,049 |
$322K |
| Z7502 |
|
8,981 |
8,265 |
$321K |
| 95811 |
|
1,174 |
1,166 |
$316K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
583 |
566 |
$310K |
| 93308 |
|
2,795 |
2,716 |
$309K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
617 |
591 |
$306K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
5,476 |
5,361 |
$303K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
3,906 |
3,861 |
$303K |
| 76830 |
Ultrasound, transvaginal |
4,026 |
3,954 |
$297K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
5,475 |
5,361 |
$296K |
| 70491 |
|
1,203 |
1,190 |
$290K |
| 88341 |
|
1,594 |
1,545 |
$283K |
| 99199 |
Unlisted special service, procedure or report |
5,283 |
4,427 |
$279K |
| 86833 |
|
2,461 |
2,380 |
$278K |
| 72128 |
|
966 |
957 |
$273K |
| 87040 |
|
6,938 |
6,362 |
$272K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
22,532 |
21,324 |
$271K |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
1,259 |
1,243 |
$269K |
| 85027 |
|
30,413 |
26,810 |
$267K |
| 75574 |
|
1,002 |
1,001 |
$265K |
| 83605 |
|
15,462 |
13,840 |
$264K |
| 81378 |
|
621 |
498 |
$262K |
| 80061 |
Lipid panel |
21,863 |
21,170 |
$261K |
| 93320 |
|
2,969 |
2,920 |
$258K |
| 87799 |
|
4,706 |
3,540 |
$258K |
| 86900 |
|
26,731 |
20,315 |
$254K |
| 86480 |
|
5,402 |
5,298 |
$253K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,755 |
2,606 |
$253K |
| 83970 |
|
6,090 |
5,897 |
$251K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,042 |
1,988 |
$251K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
27,148 |
26,419 |
$250K |
| 86901 |
|
26,219 |
19,918 |
$250K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
141 |
44 |
$249K |
| 0272 |
|
1,921 |
1,666 |
$248K |
| 83880 |
|
9,102 |
8,526 |
$246K |
| V5298 |
Hearing aid, not otherwise classified |
182 |
182 |
$245K |
| 83690 |
|
21,348 |
19,589 |
$244K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
22,602 |
19,877 |
$244K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
7,406 |
5,035 |
$242K |
| 77290 |
|
1,242 |
1,110 |
$240K |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
1,130 |
1,122 |
$240K |
| 74178 |
|
978 |
961 |
$239K |
| 73221 |
|
648 |
629 |
$234K |
| 94375 |
|
5,207 |
4,742 |
$231K |
| 85610 |
|
35,237 |
29,120 |
$231K |
| 84100 |
|
26,410 |
15,855 |
$219K |
| 77470 |
|
790 |
767 |
$218K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
3,395 |
3,382 |
$213K |
| 82728 |
|
13,128 |
11,323 |
$206K |
| 85730 |
|
17,395 |
15,783 |
$205K |
| 76536 |
|
3,148 |
3,123 |
$205K |
| 77049 |
|
354 |
354 |
$202K |
| 78830 |
|
431 |
421 |
$197K |
| 97799 |
|
9,816 |
3,129 |
$187K |
| 94729 |
|
4,024 |
3,958 |
$186K |
| G0378 |
Hospital observation service, per hour |
3,057 |
2,675 |
$186K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
3,317 |
1,993 |
$184K |
| 0121 |
|
18 |
18 |
$182K |
| 86140 |
|
19,168 |
17,256 |
$181K |
| 0760 |
|
5,857 |
5,026 |
$180K |
| 76770 |
|
2,394 |
2,356 |
$180K |
| Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
123 |
43 |
$176K |
| 77066 |
Tomosynthesis, mammo |
1,808 |
1,796 |
$173K |
| 76642 |
|
2,803 |
2,442 |
$173K |
| 93296 |
|
5,034 |
5,022 |
$170K |
| 84439 |
|
13,452 |
11,991 |
$168K |
| 73630 |
|
5,444 |
4,792 |
$160K |
| T1999 |
Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" |
38,748 |
12,007 |
$159K |
| 73610 |
|
4,271 |
3,999 |
$153K |
| 73030 |
|
5,346 |
4,911 |
$148K |
| 88342 |
|
3,430 |
3,355 |
$147K |
| 0681 |
|
283 |
283 |
$146K |
| 70549 |
|
365 |
361 |
$144K |
| 93880 |
|
1,143 |
1,123 |
$141K |
| 82378 |
|
6,176 |
4,657 |
$140K |
| 87631 |
|
2,596 |
2,532 |
$138K |
| 0710 |
|
1,657 |
1,520 |
$137K |
| 96416 |
|
1,451 |
924 |
$136K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
372 |
366 |
$136K |
| 83615 |
|
13,857 |
9,470 |
$134K |
| 82962 |
|
16,812 |
13,418 |
$134K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,750 |
1,626 |
$130K |
| 96401 |
|
3,425 |
1,694 |
$130K |
| 99152 |
|
2,721 |
2,591 |
$129K |
| 94060 |
|
2,377 |
2,342 |
$128K |
| 87517 |
|
3,233 |
3,060 |
$126K |
| 81455 |
|
57 |
57 |
$125K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,430 |
2,343 |
$123K |
| 80306 |
|
3,730 |
3,505 |
$122K |
| P9073 |
Platelets, pheresis, pathogen-reduced, each unit |
242 |
105 |
$118K |
| 83550 |
|
13,499 |
12,511 |
$118K |
| 85379 |
|
4,964 |
4,274 |
$109K |
| 82024 |
|
2,681 |
2,163 |
$107K |
| 87340 |
|
6,757 |
6,584 |
$106K |
| 87186 |
|
7,724 |
7,389 |
$105K |
| 90677 |
|
699 |
698 |
$104K |
| V2632 |
Posterior chamber intraocular lens |
901 |
863 |
$104K |
| 82533 |
|
4,064 |
3,374 |
$104K |
| 87077 |
|
11,272 |
10,585 |
$103K |
| 87150 |
|
3,990 |
3,890 |
$103K |
| 96402 |
|
3,498 |
3,266 |
$102K |
| 87486 |
|
3,488 |
3,407 |
$101K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,342 |
1,162 |
$101K |
| 87581 |
|
3,486 |
3,406 |
$101K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,762 |
1,962 |
$101K |
| 86803 |
|
5,771 |
5,660 |
$101K |
| 83540 |
|
13,938 |
12,897 |
$101K |
| 84403 |
|
3,257 |
3,066 |
$100K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
4,890 |
4,795 |
$98K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
12,170 |
6,905 |
$98K |
| 80180 |
|
8,576 |
3,689 |
$98K |
| 99153 |
Mod sedat endo service >5yrs |
1,993 |
1,926 |
$97K |
| 78264 |
|
402 |
402 |
$96K |
| 93246 |
|
3,936 |
3,883 |
$95K |
| 96411 |
|
1,961 |
1,430 |
$94K |
| 73590 |
|
2,070 |
1,948 |
$94K |
| Z7500 |
|
4,207 |
3,431 |
$94K |
| 0761 |
|
1,113 |
946 |
$94K |
| 92550 |
|
4,269 |
4,247 |
$94K |
| 72146 |
|
230 |
230 |
$93K |
| 82784 |
|
7,458 |
6,712 |
$93K |
| 73110 |
|
2,991 |
2,780 |
$93K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
15,475 |
12,712 |
$91K |
| 97165 |
|
2,426 |
2,048 |
$90K |
| 73700 |
|
389 |
363 |
$89K |
| 86704 |
|
4,858 |
4,748 |
$89K |
| 73562 |
|
3,501 |
3,035 |
$88K |
| 84153 |
|
4,629 |
4,250 |
$88K |
| 75561 |
|
167 |
166 |
$88K |
| 94618 |
|
2,421 |
2,375 |
$88K |
| 73130 |
|
2,647 |
2,403 |
$87K |
| 77080 |
|
3,453 |
3,442 |
$87K |
| J9045 |
Injection, carboplatin, 50 mg |
1,900 |
1,373 |
$87K |
| J9395 |
Injection, fulvestrant, 25 mg |
175 |
150 |
$86K |
| 87070 |
|
4,734 |
4,468 |
$85K |
| 82977 |
|
8,362 |
5,202 |
$84K |
| 74018 |
|
2,758 |
2,597 |
$84K |
| 76937 |
|
1,716 |
1,412 |
$84K |
| 93454 |
|
93 |
93 |
$84K |
| 87522 |
Neg quan hep c or qual rna |
1,737 |
1,665 |
$83K |
| J2182 |
Injection, mepolizumab, 1 mg |
26 |
24 |
$82K |
| 36415 |
Collection of venous blood by venipuncture |
52,324 |
40,188 |
$80K |
| 93990 |
|
472 |
452 |
$80K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,709 |
1,602 |
$80K |
| 82105 |
|
4,806 |
4,409 |
$79K |
| 77073 |
|
3,506 |
3,437 |
$78K |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
93 |
27 |
$78K |
| 0001A |
|
2,191 |
2,187 |
$78K |
| J1750 |
Injection, iron dextran, 50 mg |
420 |
195 |
$78K |
| 0002A |
|
1,966 |
1,963 |
$77K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
7,357 |
5,706 |
$75K |
| 77065 |
Tomosynthesis, mammo |
871 |
857 |
$75K |
| 86334 |
|
4,828 |
4,410 |
$75K |
| 86665 |
|
2,066 |
2,036 |
$74K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
9,115 |
7,937 |
$74K |
| 82565 |
|
12,124 |
11,882 |
$74K |
| 83883 |
|
4,783 |
4,280 |
$74K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
2,201 |
2,186 |
$71K |
| 76870 |
|
948 |
919 |
$70K |
| 84702 |
|
3,892 |
3,404 |
$70K |
| 82746 |
|
3,700 |
3,648 |
$68K |
| 72195 |
|
237 |
211 |
$67K |
| 73552 |
|
1,525 |
1,418 |
$65K |
| 82570 |
|
13,900 |
12,692 |
$65K |
| 93925 |
|
448 |
443 |
$65K |
| 81003 |
|
15,629 |
9,825 |
$65K |
| 73564 |
|
1,484 |
1,381 |
$64K |
| 96409 |
|
1,158 |
820 |
$64K |
| 87536 |
|
828 |
801 |
$63K |
| 73502 |
|
2,049 |
1,946 |
$63K |
| 86706 |
|
3,715 |
3,619 |
$62K |
| J9190 |
Injection, fluorouracil, 500 mg |
2,764 |
1,464 |
$62K |
| 90715 |
|
2,036 |
2,018 |
$61K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
10,660 |
9,644 |
$61K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
438 |
430 |
$60K |
| 72100 |
|
2,228 |
2,165 |
$59K |
| 86301 |
|
3,868 |
2,811 |
$58K |
| A9595 |
Piflufolastat f-18, diagnostic, 1 millicurie |
15 |
14 |
$57K |
| 72170 |
|
1,962 |
1,927 |
$57K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
4,750 |
3,051 |
$56K |
| 96910 |
|
1,586 |
264 |
$56K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
1,499 |
554 |
$56K |
| 81479 |
Unlisted molecular pathology procedure |
498 |
405 |
$55K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
5,543 |
3,167 |
$55K |
| J9267 |
Injection, paclitaxel, 1 mg |
1,276 |
715 |
$54K |
| 82550 |
|
5,362 |
4,878 |
$54K |
| 77387 |
|
666 |
131 |
$54K |
| 90686 |
|
2,605 |
2,577 |
$53K |
| 86360 |
|
1,282 |
1,252 |
$52K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,236 |
3,197 |
$52K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
6,998 |
6,789 |
$51K |
| 93922 |
|
659 |
656 |
$51K |
| 73080 |
|
1,543 |
1,478 |
$50K |
| 86304 |
|
2,834 |
2,286 |
$50K |
| 82805 |
|
1,176 |
1,104 |
$49K |
| Z7610 |
|
15,256 |
5,578 |
$49K |
| 82670 |
|
1,064 |
1,015 |
$47K |
| 93321 |
|
1,138 |
1,096 |
$46K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
37 |
37 |
$46K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
5,858 |
4,914 |
$46K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
1,459 |
585 |
$46K |
| 95700 |
|
109 |
91 |
$46K |
| 95708 |
|
56 |
56 |
$45K |
| 86359 |
|
1,308 |
1,276 |
$45K |
| 86235 |
|
1,056 |
1,011 |
$44K |
| 95913 |
|
112 |
112 |
$44K |
| 77280 |
|
543 |
516 |
$44K |
| 86160 |
|
2,245 |
2,122 |
$44K |
| 85652 |
|
11,316 |
10,833 |
$44K |
| 96139 |
|
206 |
205 |
$43K |
| 93926 |
|
413 |
406 |
$43K |
| 81025 |
|
4,593 |
4,427 |
$43K |
| 88184 |
|
907 |
856 |
$43K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,980 |
1,465 |
$42K |
| 73560 |
|
1,618 |
1,484 |
$41K |
| J2704 |
Injection, propofol, 10 mg |
3,863 |
3,288 |
$41K |
| 82607 |
|
5,174 |
5,053 |
$41K |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
615 |
612 |
$40K |
| J9171 |
Injection, docetaxel, 1 mg |
271 |
188 |
$40K |
| 95886 |
|
531 |
526 |
$40K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
655 |
389 |
$40K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
5,103 |
3,632 |
$40K |
| 88360 |
|
763 |
735 |
$40K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
6,897 |
5,254 |
$39K |
| 82248 |
|
5,340 |
4,533 |
$39K |
| 86038 |
|
2,891 |
2,854 |
$39K |
| 93225 |
|
761 |
747 |
$39K |
| 85384 |
|
1,753 |
1,063 |
$39K |
| 77370 |
|
187 |
185 |
$38K |
| 91122 |
|
429 |
428 |
$38K |
| 73501 |
|
1,516 |
1,487 |
$38K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
237 |
216 |
$38K |
| 36430 |
|
419 |
270 |
$38K |
| 86977 |
|
717 |
693 |
$38K |
| J3111 |
Injection, romosozumab-aqqg, 1 mg |
24 |
24 |
$37K |
| 74019 |
|
639 |
622 |
$37K |
| 86708 |
|
2,181 |
2,130 |
$36K |
| 84550 |
|
5,103 |
4,210 |
$36K |
| 64615 |
|
1,247 |
1,241 |
$36K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
929 |
920 |
$36K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,792 |
4,236 |
$35K |
| 0012A |
|
913 |
911 |
$35K |
| 74220 |
|
708 |
705 |
$35K |
| 72040 |
|
1,121 |
1,099 |
$35K |
| J9075 |
Injection, cyclophosphamide, not otherwise specified, 5 mg |
201 |
64 |
$34K |
| J1815 |
Injection, insulin, per 5 units |
1,128 |
709 |
$33K |
| 96377 |
|
809 |
678 |
$33K |
| 86769 |
|
833 |
806 |
$33K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
2,960 |
2,616 |
$32K |
| 84432 |
|
1,563 |
1,463 |
$32K |
| 94726 |
|
614 |
609 |
$31K |
| 96133 |
|
199 |
197 |
$31K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
2,861 |
2,800 |
$31K |
| 88307 |
|
333 |
326 |
$31K |
| 94644 |
|
758 |
728 |
$30K |
| J2785 |
Injection, regadenoson, 0.1 mg |
171 |
162 |
$30K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
769 |
740 |
$30K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
382 |
364 |
$30K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
610 |
584 |
$30K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
1,501 |
1,457 |
$29K |
| 0011A |
|
974 |
973 |
$29K |
| 76604 |
|
502 |
499 |
$29K |
| 86225 |
|
1,658 |
1,617 |
$29K |
| 76882 |
|
1,014 |
927 |
$29K |
| 72082 |
|
734 |
720 |
$28K |
| 86664 |
|
1,145 |
1,130 |
$28K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
5,751 |
5,328 |
$28K |
| 88312 |
|
776 |
759 |
$28K |
| 78306 |
|
169 |
168 |
$27K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
4,804 |
4,643 |
$27K |
| 87205 |
|
3,195 |
2,919 |
$27K |
| 91065 |
|
499 |
463 |
$27K |
| 83525 |
|
1,550 |
1,539 |
$27K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,823 |
2,435 |
$26K |
| 86787 |
|
1,123 |
1,092 |
$26K |
| J3489 |
Injection, zoledronic acid, 1 mg |
795 |
764 |
$26K |
| 90694 |
|
1,712 |
1,704 |
$26K |
| 83516 |
|
2,211 |
2,160 |
$26K |
| 84132 |
|
2,911 |
2,780 |
$25K |
| 96116 |
|
343 |
339 |
$25K |
| 84425 |
|
1,508 |
1,483 |
$25K |
| 85045 |
|
4,856 |
4,007 |
$25K |
| 80069 |
|
2,791 |
2,564 |
$25K |
| 86870 |
|
695 |
512 |
$24K |
| 70552 |
|
47 |
45 |
$24K |
| A9581 |
Injection, gadoxetate disodium, 1 ml |
144 |
139 |
$24K |
| 73090 |
|
816 |
789 |
$24K |
| 84295 |
|
2,711 |
2,610 |
$23K |
| 87102 |
|
1,571 |
1,438 |
$23K |
| 94010 |
|
359 |
345 |
$23K |
| 86780 |
|
2,144 |
2,043 |
$23K |
| 80177 |
|
1,882 |
1,815 |
$23K |
| 84156 |
|
6,425 |
5,638 |
$23K |
| J9070 |
Cyclophosphamide, 100 mg |
101 |
38 |
$22K |
| 96368 |
|
591 |
478 |
$22K |
| 76512 |
|
444 |
400 |
$22K |
| 82947 |
|
2,979 |
2,869 |
$22K |
| 76801 |
|
282 |
271 |
$21K |
| 82330 |
|
1,174 |
1,027 |
$21K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
284 |
257 |
$21K |
| 86663 |
|
1,134 |
1,119 |
$21K |
| 0003A |
|
517 |
517 |
$21K |
| 92134 |
|
10,730 |
10,341 |
$21K |
| 81373 |
|
135 |
93 |
$20K |
| 88142 |
|
2,184 |
2,178 |
$20K |
| 92567 |
|
1,350 |
1,337 |
$20K |
| 93280 |
|
1,305 |
1,269 |
$20K |
| 87116 |
|
1,271 |
1,056 |
$20K |
| 80076 |
|
1,814 |
1,728 |
$20K |
| 73140 |
|
953 |
892 |
$20K |
| 95819 |
|
93 |
93 |
$20K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
414 |
311 |
$20K |
| 31231 |
|
1,173 |
1,163 |
$19K |
| 88323 |
|
438 |
430 |
$19K |
| 85014 |
|
3,000 |
2,878 |
$19K |
| 82042 |
|
7,509 |
7,178 |
$19K |
| 83001 |
|
743 |
724 |
$18K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
2,876 |
2,661 |
$18K |
| 86141 |
|
1,654 |
1,619 |
$18K |
| 90732 |
|
344 |
336 |
$18K |
| 97116 |
|
1,290 |
851 |
$18K |
| 80195 |
|
1,182 |
712 |
$18K |
| 11043 |
|
795 |
470 |
$18K |
| 31579 |
|
497 |
494 |
$17K |
| 95911 |
|
52 |
52 |
$17K |
| 36592 |
|
284 |
162 |
$17K |
| 71271 |
|
259 |
258 |
$17K |
| J1644 |
Injection, heparin sodium, per 1000 units |
2,565 |
1,572 |
$17K |
| 82140 |
|
858 |
745 |
$17K |
| 88240 |
|
998 |
890 |
$17K |
| 86255 |
|
629 |
625 |
$17K |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
270 |
270 |
$17K |
| 76775 |
|
219 |
215 |
$16K |
| 85651 |
|
1,934 |
1,904 |
$16K |
| 90750 |
|
80 |
80 |
$16K |
| 51798 |
|
1,883 |
1,852 |
$16K |
| 84480 |
|
788 |
743 |
$16K |
| 74230 |
|
300 |
296 |
$16K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
3,943 |
3,524 |
$16K |
| 92612 |
|
130 |
128 |
$16K |
| 73060 |
|
519 |
504 |
$15K |
| 94621 |
|
51 |
51 |
$15K |
| 83695 |
|
1,358 |
1,347 |
$15K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,465 |
1,391 |
$15K |
| 83010 |
|
1,031 |
902 |
$15K |
| 92083 |
|
2,959 |
2,909 |
$15K |
| 96132 |
|
169 |
168 |
$15K |
| 0064A |
|
412 |
412 |
$15K |
| 87529 |
|
351 |
339 |
$15K |
| 74328 |
|
59 |
58 |
$14K |
| 86705 |
|
983 |
964 |
$14K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
411 |
383 |
$14K |
| 88173 |
|
222 |
219 |
$14K |
| 73718 |
|
73 |
67 |
$14K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
52 |
48 |
$14K |
| 90670 |
|
165 |
159 |
$14K |
| 87493 |
|
458 |
450 |
$14K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
1,347 |
668 |
$14K |
| 88304 |
|
582 |
578 |
$14K |
| 92504 |
|
839 |
804 |
$13K |
| 86696 |
|
850 |
824 |
$13K |
| 92526 |
|
467 |
421 |
$13K |
| 86695 |
|
850 |
824 |
$13K |
| 86644 |
|
992 |
978 |
$13K |
| 86003 |
|
115 |
112 |
$13K |
| 70480 |
|
68 |
68 |
$13K |
| 86357 |
|
397 |
385 |
$12K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
1,652 |
1,010 |
$12K |
| 86592 |
|
2,258 |
2,227 |
$12K |
| 90675 |
|
31 |
12 |
$12K |
| 80175 |
|
1,057 |
1,025 |
$12K |
| 83090 |
|
833 |
822 |
$11K |
| 86355 |
|
396 |
384 |
$11K |
| J1790 |
Injection, droperidol, up to 5 mg |
771 |
705 |
$11K |
| 76942 |
|
152 |
143 |
$11K |
| 88112 |
|
270 |
267 |
$11K |
| 82150 |
|
761 |
596 |
$11K |
| 91200 |
|
388 |
388 |
$11K |
| 94727 |
|
305 |
295 |
$11K |
| 95983 |
|
275 |
264 |
$11K |
| 36591 |
|
859 |
692 |
$11K |
| 70481 |
|
24 |
24 |
$10K |
| 86431 |
|
1,377 |
1,356 |
$10K |
| 72110 |
|
294 |
292 |
$10K |
| 92020 |
|
726 |
720 |
$10K |
| J1940 |
Injection, furosemide, up to 20 mg |
1,972 |
1,747 |
$10K |
| 97162 |
|
787 |
771 |
$10K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
41 |
41 |
$10K |
| J2060 |
Injection, lorazepam, 2 mg |
1,652 |
1,312 |
$10K |
| 83993 |
|
637 |
634 |
$10K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
193 |
181 |
$10K |
| 97163 |
|
353 |
352 |
$9K |
| 92136 |
|
862 |
860 |
$9K |
| 97803 |
|
1,230 |
1,185 |
$9K |
| 95800 |
|
62 |
62 |
$9K |
| 83921 |
|
903 |
892 |
$9K |
| J9206 |
Injection, irinotecan, 20 mg |
296 |
111 |
$9K |
| 94645 |
|
117 |
113 |
$9K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
192 |
90 |
$9K |
| 96138 |
|
204 |
203 |
$9K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,344 |
1,011 |
$8K |
| 84146 |
|
276 |
271 |
$8K |
| 95910 |
|
29 |
29 |
$8K |
| 82040 |
|
1,443 |
1,402 |
$8K |
| 92523 |
|
64 |
64 |
$8K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
110 |
58 |
$8K |
| 82107 |
|
133 |
130 |
$8K |
| 70487 |
|
13 |
13 |
$8K |
| 86308 |
|
696 |
691 |
$7K |
| 89050 |
|
778 |
653 |
$7K |
| 90662 |
|
1,089 |
1,028 |
$7K |
| 84478 |
|
722 |
544 |
$7K |
| 87206 |
|
1,237 |
882 |
$7K |
| 86335 |
|
445 |
438 |
$7K |
| 73200 |
|
41 |
39 |
$7K |
| 95885 |
|
139 |
139 |
$7K |
| 84703 |
|
297 |
272 |
$7K |
| 97161 |
|
735 |
708 |
$7K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
145 |
144 |
$7K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
19 |
15 |
$7K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,025 |
1,576 |
$7K |
| 84630 |
|
496 |
494 |
$6K |
| 88237 |
|
94 |
94 |
$6K |
| 70355 |
|
170 |
170 |
$6K |
| 80074 |
|
65 |
64 |
$6K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
1,142 |
1,134 |
$6K |
| 72190 |
|
116 |
112 |
$6K |
| 92585 |
|
24 |
24 |
$6K |
| 95924 |
|
39 |
39 |
$6K |
| 76519 |
|
170 |
168 |
$6K |
| 87533 |
|
104 |
64 |
$6K |
| 96376 |
|
1,017 |
758 |
$6K |
| 72070 |
|
134 |
131 |
$6K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
66 |
65 |
$6K |
| C1769 |
Guide wire |
187 |
169 |
$5K |
| 86147 |
|
130 |
130 |
$5K |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
34 |
34 |
$5K |
| 71020 |
|
104 |
86 |
$5K |
| 73521 |
|
135 |
134 |
$5K |
| 92133 |
|
2,766 |
2,730 |
$5K |
| 86146 |
|
129 |
129 |
$5K |
| 85347 |
|
252 |
233 |
$5K |
| 82010 |
|
395 |
376 |
$5K |
| 73000 |
|
142 |
135 |
$5K |
| 87081 |
|
479 |
456 |
$5K |
| 87015 |
|
471 |
363 |
$5K |
| 82610 |
|
429 |
388 |
$5K |
| 85670 |
|
616 |
321 |
$5K |
| 90656 |
|
200 |
200 |
$5K |
| 82525 |
|
395 |
393 |
$5K |
| 31575 |
|
123 |
119 |
$5K |
| 82785 |
|
227 |
223 |
$5K |
| 92201 |
|
169 |
158 |
$5K |
| 0301 |
|
59 |
53 |
$4K |
| 72050 |
|
99 |
99 |
$4K |
| 80158 |
|
300 |
225 |
$4K |
| 76380 |
|
41 |
41 |
$4K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
15 |
14 |
$4K |
| 82274 |
|
710 |
706 |
$4K |
| 99215 |
Prolong outpt/office vis |
58 |
51 |
$4K |
| 84300 |
|
603 |
563 |
$4K |
| 77399 |
|
84 |
83 |
$4K |
| 0053A |
|
93 |
93 |
$4K |
| 76881 |
|
43 |
41 |
$4K |
| 88365 |
|
38 |
37 |
$4K |
| 80299 |
|
184 |
176 |
$3K |
| 0071A |
|
85 |
85 |
$3K |
| 93284 |
|
101 |
99 |
$3K |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
299 |
287 |
$3K |
| 20610 |
|
104 |
98 |
$3K |
| 0305 |
|
67 |
64 |
$3K |
| 84590 |
|
229 |
227 |
$3K |
| 17311 |
|
90 |
89 |
$3K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
30 |
29 |
$3K |
| 82390 |
|
241 |
239 |
$3K |
| 92604 |
|
48 |
47 |
$3K |
| 80164 |
|
216 |
205 |
$3K |
| 88377 |
|
16 |
14 |
$3K |
| 95909 |
|
14 |
14 |
$3K |
| 86777 |
|
166 |
165 |
$3K |
| 93242 |
|
165 |
162 |
$3K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
48 |
43 |
$3K |
| 77001 |
|
25 |
25 |
$3K |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
192 |
184 |
$3K |
| 0072A |
|
70 |
70 |
$3K |
| 85613 |
|
168 |
102 |
$3K |
| 86200 |
|
485 |
478 |
$3K |
| 76514 |
|
972 |
959 |
$3K |
| A4649 |
Surgical supply; miscellaneous |
17 |
16 |
$3K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
203 |
166 |
$3K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
56 |
56 |
$3K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
210 |
132 |
$3K |
| 0051A |
|
66 |
66 |
$3K |
| J0173 |
Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg |
98 |
88 |
$3K |
| 86376 |
|
182 |
179 |
$3K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
272 |
254 |
$3K |
| 92225 |
|
59 |
52 |
$3K |
| 73120 |
|
175 |
112 |
$3K |
| 91010 |
|
93 |
93 |
$2K |
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
13 |
12 |
$2K |
| 83520 |
|
177 |
168 |
$2K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
564 |
501 |
$2K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
129 |
129 |
$2K |
| 90739 |
|
14 |
14 |
$2K |
| 0278 |
|
36 |
36 |
$2K |
| 81002 |
|
776 |
738 |
$2K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
80 |
73 |
$2K |
| 82085 |
|
267 |
257 |
$2K |
| 74240 |
|
38 |
38 |
$2K |
| 20611 |
|
78 |
78 |
$2K |
| 84402 |
|
65 |
65 |
$2K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
16 |
12 |
$2K |
| 86148 |
|
78 |
77 |
$2K |
| 82985 |
|
173 |
172 |
$2K |
| 92226 |
|
42 |
27 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
5,517 |
4,985 |
$2K |
| 0636 |
|
48 |
38 |
$2K |
| 85390 |
|
172 |
172 |
$2K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
127 |
116 |
$2K |
| J1250 |
Injection, dobutamine hydrochloride, per 250 mg |
137 |
136 |
$2K |
| 84460 |
|
245 |
239 |
$2K |
| 92273 |
|
13 |
13 |
$2K |
| 73100 |
|
118 |
72 |
$2K |
| 88264 |
|
26 |
26 |
$2K |
| 82103 |
|
132 |
132 |
$1K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
15 |
15 |
$1K |
| 92229 |
|
84 |
84 |
$1K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
256 |
183 |
$1K |
| 93283 |
|
39 |
39 |
$1K |
| 71010 |
|
19 |
18 |
$1K |
| 83002 |
|
53 |
51 |
$1K |
| 88313 |
|
57 |
50 |
$1K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
44 |
27 |
$1K |
| 80169 |
|
156 |
105 |
$1K |
| 93978 |
|
13 |
13 |
$1K |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
83 |
81 |
$1K |
| 31645 |
|
38 |
36 |
$1K |
| 73600 |
|
47 |
41 |
$1K |
| 97802 |
|
165 |
165 |
$1K |
| 82232 |
|
103 |
96 |
$1K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
173 |
165 |
$1K |
| 92060 |
|
116 |
114 |
$1K |
| 90653 |
|
260 |
260 |
$1K |
| 84134 |
|
64 |
64 |
$1K |
| 92002 |
|
25 |
25 |
$1K |
| 84681 |
|
43 |
41 |
$1K |
| 82747 |
|
55 |
50 |
$1K |
| 64566 |
|
71 |
49 |
$1K |
| 86880 |
|
90 |
76 |
$1K |
| 86036 |
|
44 |
44 |
$1K |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
136 |
132 |
$1K |
| 86039 |
|
85 |
85 |
$998.04 |
| 90791 |
Psychiatric diagnostic evaluation |
13 |
13 |
$984.40 |
| 76999 |
|
15 |
13 |
$980.00 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
54 |
36 |
$974.26 |
| 92025 |
|
577 |
567 |
$931.44 |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
34 |
34 |
$916.45 |
| 91322 |
|
199 |
199 |
$881.81 |
| 82310 |
|
165 |
157 |
$879.00 |
| 83935 |
|
120 |
113 |
$873.88 |
| 82542 |
|
25 |
25 |
$860.88 |
| 84165 |
|
100 |
91 |
$854.84 |
| 0306 |
|
27 |
26 |
$846.53 |
| 83930 |
|
91 |
86 |
$842.56 |
| 86015 |
|
67 |
67 |
$839.46 |
| 73620 |
|
28 |
25 |
$834.56 |
| J1953 |
Injection, levetiracetam, 10 mg |
48 |
42 |
$820.62 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
221 |
219 |
$818.90 |
| 88280 |
|
26 |
26 |
$797.16 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
154 |
118 |
$795.06 |
| 90480 |
|
206 |
206 |
$766.65 |
| G0008 |
Administration of influenza virus vaccine |
2,295 |
2,231 |
$765.08 |
| 87184 |
|
63 |
63 |
$723.42 |
| 83519 |
|
108 |
106 |
$689.22 |
| 36600 |
|
105 |
101 |
$658.23 |
| 67228 |
|
12 |
12 |
$641.46 |
| 84207 |
|
41 |
40 |
$637.22 |
| 86635 |
|
44 |
42 |
$606.20 |
| 84520 |
|
109 |
100 |
$606.01 |
| 0949 |
|
33 |
27 |
$604.72 |
| 82465 |
|
67 |
58 |
$600.22 |
| 95836 |
|
13 |
13 |
$595.93 |
| 88172 |
|
49 |
49 |
$587.24 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
38 |
37 |
$563.20 |
| 93298 |
|
13 |
12 |
$558.04 |
| 88311 |
|
83 |
79 |
$540.39 |
| 84270 |
|
13 |
13 |
$535.94 |
| 82272 |
|
192 |
183 |
$497.81 |
| 99205 |
Prolong outpt/office vis |
13 |
12 |
$493.90 |
| 97003 |
|
13 |
12 |
$492.32 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
19 |
12 |
$478.96 |
| 0324 |
|
13 |
12 |
$461.19 |
| 91037 |
|
12 |
12 |
$455.51 |
| 0031A |
|
13 |
13 |
$445.00 |
| 86902 |
|
34 |
24 |
$441.87 |
| 0296T |
|
90 |
85 |
$431.72 |
| 82787 |
|
13 |
12 |
$426.57 |
| 86381 |
|
38 |
38 |
$411.16 |
| 86905 |
|
13 |
12 |
$409.46 |
| 84155 |
|
155 |
142 |
$404.48 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
29 |
28 |
$400.47 |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
12 |
12 |
$392.37 |
| 97535 |
Self-care/home management training, each 15 minutes |
96 |
84 |
$385.65 |
| 83721 |
|
38 |
38 |
$378.44 |
| 87338 |
|
112 |
112 |
$335.68 |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
24 |
24 |
$334.23 |
| 84450 |
|
27 |
25 |
$327.75 |
| 95874 |
|
14 |
14 |
$317.44 |
| 82340 |
|
45 |
45 |
$302.82 |
| J9370 |
Vincristine sulfate, 1 mg |
17 |
12 |
$287.79 |
| 17110 |
|
102 |
102 |
$284.37 |
| 92235 |
|
12 |
12 |
$273.64 |
| 92285 |
|
59 |
54 |
$265.14 |
| 82668 |
|
12 |
12 |
$243.31 |
| 11900 |
|
55 |
52 |
$238.45 |
| 84446 |
|
12 |
12 |
$234.84 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
20 |
16 |
$225.81 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
4,084 |
3,436 |
$207.44 |
| 89051 |
|
32 |
27 |
$194.10 |
| J1836 |
Injection, metronidazole, 10 mg |
17 |
13 |
$123.35 |
| 96379 |
|
1,036 |
760 |
$112.58 |
| J2305 |
Injection, nitroglycerin, 5 mg |
12 |
12 |
$111.16 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
48 |
44 |
$101.78 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
12 |
12 |
$98.52 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
20 |
17 |
$74.14 |
| 82247 |
|
14 |
13 |
$73.25 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
36 |
25 |
$64.00 |
| 69210 |
|
12 |
12 |
$61.78 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
78 |
67 |
$60.96 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
15 |
12 |
$54.70 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
13 |
12 |
$53.54 |
| 82435 |
|
26 |
26 |
$51.27 |
| J7070 |
Infusion, d5w, 1000 cc |
76 |
44 |
$47.45 |
| 82523 |
|
50 |
50 |
$43.89 |
| 11721 |
|
25 |
25 |
$42.83 |
| 84080 |
|
65 |
65 |
$38.78 |
| 97010 |
|
20 |
12 |
$25.96 |
| C9257 |
Injection, bevacizumab, 0.25 mg |
80 |
78 |
$14.59 |
| 80235 |
|
13 |
13 |
$12.23 |
| G0009 |
Administration of pneumococcal vaccine |
351 |
338 |
$9.91 |
| J3480 |
Injection, potassium chloride, per 2 meq |
19 |
15 |
$0.85 |
| Q0247 |
Injection, sotrovimab, 500 mg |
18 |
14 |
$0.11 |
| 0250R |
|
236 |
198 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
62 |
57 |
$0.00 |
| 0134A |
|
46 |
46 |
$0.00 |
| 91306 |
|
15 |
15 |
$0.00 |
| 91301 |
|
15 |
15 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
65 |
63 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
343 |
327 |
$0.00 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
12 |
12 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
331 |
315 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
38 |
37 |
$0.00 |
| 0124A |
|
15 |
15 |
$0.00 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
12 |
12 |
$0.00 |
| 90780 |
|
27 |
24 |
$0.00 |